The relatively immune-privileged status of the eye makes it an interesting target for gene delivery. Gene delivery to the eye using viral vectors via subretinal and intravitreal injections has been extensively investigated. Recently, the safety of recombinant adeno-associated virus vector expressing RPE65 complementary DNA (cDNA) in a limited clinical trial of three patients has also been reported. Nanotechnology-based non-viral vectors offer the advantages of safety and flexibility in terms of loading capacity and delivery system design compared with viral vectors. An ideal non-viral vector should be non-toxic, efficiently taken up into the target cells and conducive to gene expression, and should protect the gene against enzymatic degradation. Multiple kinds of nanotechnology-based non-viral vectors have been investigated for potential applications for gene delivery to the eye, namely nanoplexes, dendrimers, micelles, nanoparticles and liposomes. This article summarises and discusses key advances in the application of nanotechnology for gene delivery to the eye.
The gene expression pattern in the eye after intravenous administration of a gene delivery system depends on the delivery system design.
Pegylated liposomes resulted in the expression of β-galactosidase in multiple tissues -namely the ciliary body, iris, sebaceous gland, corneal epithelium and outer retina -at 48 hours after intravenous administration.
14 Recent studies from our group indicated that transferrin (Tf) and/or arginine-glycine-aspartic acid (RGD) peptide functionalised poly(lactide-co-glycolide) (PLGA) nanoparticles result in effective gene delivery to the back of the eye after intravenous injection. 13, 17 Thus, the route of administration plays a critical role in the gene expression pattern within the eye.
Nanosystems for Gene Delivery to the Eye
Evidence to date indicates the suitability of nanosystems in enhancing the delivery of nucleic acids including oligonucleotides and genes to the tissues of the eye. The nanosystems that have been investigated for delivering genes to the eye include nanoplexes, dendrimers, micelles, nanoparticles and liposomes (see Figure 2 ). Key advances in the use of nanotechnology for gene delivery to the eye are summarised in Table 1 .
Nanoplexes in Ocular Gene Delivery
Nanoplexes are complexes of the therapeutic macromolecule with one or more carrier materials. 18 Cationic polymers such as polyethyleneimine (PEI) are commonly used to complex and condense DNA. 19 The positively charged groups on the polymer interact electrostatically with the negatively charged phosphate groups in the backbone of the DNA molecule, allowing compaction of DNA and, hence, better transfection.
Nanoplexes have been investigated for improving the outcomes of glaucoma filtration surgery, which is complicated by excessive scarring during wound healing. The scarring can eventually lead to obliteration of surgically created subconjunctival filtration space or bleb for the passage of aqueous humour. Inhibition of transforming growth factor-β2 (TGF-β2) by administration of nano-sized complexes of PEI and anti-TGF-β2 oligonucleotide significantly improves the outcome of glaucoma surgery. 20 The nanocomplexes (220±40nm) administered following encapsulation in porous particles sustained the release of oligonucleotide for 15 days and enhanced the intracellular penetration of the oligonucleotide upon subconjunctival administration of particle suspension in pigmented Fauve de Bourgogne female rabbits. The clinical evaluation of these rabbits was based on the overall inflammatory state of the eye and the time to filtering bleb failure.
Nanoplexes have also been applied to rescue degenerating photoreceptors. 21 Human basic fibroblast growth factor-2 (hFGF2) plasmid was condensed with two synthetic oligopeptides, K8 and JTS-1.
Subretinal injection of the complexed DNA into three-week-old dystrophic Royal College of Surgeons (RCS) rats resulted in delayed photoreceptor cell degeneration 60 days after injection. The average analysed field points with delayed cell dystrophy represent 14-17% of the retinal surface compared with 2.6 and 4% in vector-and vehicleinjected eyes, respectively.
Dendrimers for Ocular Gene Delivery
Dendrimers -from the Greek dendron (tree) and meros (part) -consist of a central core molecule from which a number of highly branched tree-like arms originate in an ordered and symmetrical fashion. An interesting report by Liaw et al. 24 showed the delivery of reporter lacZ gene after topical dosing in mice and rabbits. The micelles were formed using poly(ethylene oxide)-poly(propylene oxide)-poly(ethyleneoxide) triblock co-polymers. The micelles had an average size of 160nm and a zeta potential of -4.4mV. After two days of topical instillation three times a day, the most intense gene expression was observed on days two to three in the iris, sclera, conjunctiva and lateral rectus muscle in rabbits. In mice, gene expression was also observed in intraocular tissues such as the anterior chamber and the retinal pigment epithelium.
Nanoparticles for Ocular Gene Delivery
Nanoparticles are spherical particles with diameters in the nanometer size range. They can be prepared with lipids, proteins, polysaccharides or polymers, 25 and can be broadly classified as nanospheres or nanocapsules: nanospheres are nanoparticles with drug or gene molecules dispersed in a carrier matrix, while nanocapsules are composed of a reservoir of drug solution or solid coated by a rate-limiting layer. 26 Thus, nanocapsules have a distinct core containing drug and an outer shell made up of a membrane.
Our research has made significant contributions in proving therapeutic efficacy and gene delivery to the eye using nanoparticles.
We are investigating the use of albumin (natural) and biodegradable- Gene expression peaked at 3 days after injection and lasted for at least 7 days.
Intravenous
Mice Pegylated immunoliposomes resulted in widespread expression of β-galactosidase gene loaded in the 14 ciliary body, iris, sebaceous glands of tarsal plate and retina.
CNV = choroidal neovasculrisation; HVJ = haemagglutinating virus of Japan; mRNA = messenger RNA; TGF-β2 = transforming growth factor-β2; VEGF = vascular endothelial growth factor.
system offer the advantages of an established safety profile, biodegradability and potential clinical viability. 27 Biodegradable synthetic polymers such as PLGA and poly(lactide) (PLA) offer an additional platform for preparing nanoparticles for nucleic acid delivery. Several pharmaceutical products containing these polymers are approved for parenteral administration. Currently, Posurdex ® , an intravitreal implant system based on these polymers, is undergoing clinical trials for the delivery of a low-molecular-weight drug.
Albumin nanoparticles loaded with Cu, Zn superoxide dismutase plasmid (SOD1) exhibited transfection efficiency as high as 80% in ARPE-19 cells. 9 We encapsulated SOD1 plasmid in human serum albumin nanoparticles and demonstrated that these particles with a diameter of about 150nm sustain the release of the plasmid, protect it against serum and nuclease degradation and allow in vitro . 29 The nanoparticles also successfully transfected retinal pigment epithelium in vivo upon intravitreal injection in male Lewis rats. 29 Even inorganic nanoparticles such as those made of iron oxide have potential for enhancing gene transfection. Streptavidin-coated superparamagnetic iron oxide nanoparticles can be conjugated to biotin-labelled DNA fragments for enhancing gene transfection. 30 Using these layered particles of 100nm, gene transfection could be enhanced in an immortalised human hepatoma cell line (Huh-7) and adult retinal endothelial cell lines from dog and human sources.
However, the toxicity of iron oxide particles has to be evaluated carefully prior to therapeutic applications.
Liposomes for Ocular Gene Delivery
Liposomes are vesicles consisting of hydrated phospholipid bilayers designed to entrap drug in either the core or the bilayer. Based on 
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Although a number of studies have investigated the delivery of reporter genes to the eye using liposomes after administration by various routes (see Table 1 ), the therapeutic efficacy of this system has yet to be investigated. An interesting study using liposomes 
Other Delivery Systems
Other non-viral approaches for gene delivery to the eye include iontophoresis, 33- 
